IMMUNEERING CORPORATIO

Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations

12 12 2023 07:00:00 提供 Nasdaq GlobeNewswire

Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference

20 11 2023 15:05:00 提供 Nasdaq GlobeNewswire

Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates

09 11 2023 15:05:01 提供 Nasdaq GlobeNewswire

Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference

12 10 2023 15:05:00 提供 Nasdaq GlobeNewswire

Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

04 10 2023 15:05:00 提供 Nasdaq GlobeNewswire

Immuneering to Present at the Morgan Stanley Healthcare Conference

06 9 2023 07:00:00 提供 Nasdaq GlobeNewswire

Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates

03 8 2023 15:05:01 提供 Nasdaq GlobeNewswire

Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors

05 6 2023 07:00:01 提供 Nasdaq GlobeNewswire

Immuneering to Present at the Jefferies Healthcare Conference

30 5 2023 07:00:01 提供 Nasdaq GlobeNewswire

Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates

04 5 2023 15:05:02 提供 Nasdaq GlobeNewswire

Immuneering Announces $30 Million Underwritten Offering

18 4 2023 08:24:15 提供 Nasdaq GlobeNewswire

Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline

18 4 2023 08:00:02 提供 Nasdaq GlobeNewswire

Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference

12 4 2023 15:05:00 提供 Nasdaq GlobeNewswire

Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

05 4 2023 07:00:00 提供 Nasdaq GlobeNewswire

Immuneering Appoints Harold E. Brakewood as Chief Business Officer

28 3 2023 07:00:01 提供 Nasdaq GlobeNewswire

Immuneering to Present Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023

14 3 2023 15:30:00 提供 Nasdaq GlobeNewswire

Immuneering Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

06 3 2023 15:05:00 提供 Nasdaq GlobeNewswire

Immuneering Presents Preclinical Data with Lead Program IMM-1-104 Supporting Universal-RAS Activity

05 3 2023 17:30:00 提供 Nasdaq GlobeNewswire

Immuneering Announces Participation in March Investor Conferences

28 2 2023 07:00:02 提供 Nasdaq GlobeNewswire

Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

27 2 2023 07:00:01 提供 Nasdaq GlobeNewswire